article thumbnail

Oral COVID Agents

Pharmacy Friday Pearls

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

article thumbnail

The Checkup by Singlecare - Untitled Article

The Checkup by Singlecare

Examples of statins that can interact with Paxlovid include: Zocor ( simvastatin ) Lipitor ( atorvastatin ) Mevacor ( lovastatin ) Crestor ( rosuvastatin ) Simvastatin and lovastatin should not be taken at least 12 hours before the first Paxlovid dose, throughout treatment, and five days after completing Paxlovid.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Most Effective Medications to Treat Folliculitis

BuzzRx

Please continue reading to learn about some of the most effective treatments for folliculitis. If you have certain health conditions or are taking medications that weaken the immune system, treatment is almost always warranted, as your body cannot clear infections well enough compared to others. What is folliculitis?

article thumbnail

Nine for 2022: International issues that are compelling, new or changed in 2022

pharmaphorum

The next phase of the Covid-19 – from vaccines to treatments. New COVID-19 treatments will also be available in 2022, but they are not a panacea. Pfizer reported in early December that Paxlovid, now also approved in US, Europe and UK, retained 89% efficacy in preventing hospitalisation and death from an earlier readout.

article thumbnail

Medications That May Cause Body Odor as a Side Effect

BuzzRx

Examples include HIV medications , certain antidepressants, opioids, neuroleptics (antipsychotic medications), and antiseptic mouthwashes, which reduce moisture and cause dry mouth. However, there is no evidence of a lasting improvement in excessive sweating with these treatments. Examples include bisphosphonates and lithium.

article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.